Profile data is unavailable for this security.
About the company
Shandong Lukang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The Company's primary products include pharmaceutical preparation products, semi-synthetic antibiotic raw materials, veterinary antibiotics and antibiotic raw materials and others. The Company is also involved in the production and distribution of pharmaceutical intermediates. The Company distributes its products in domestic and overseas markets.
- Revenue in CNY (TTM)6.28bn
- Net income in CNY267.79m
- Incorporated1993
- Employees6.48k
- LocationShandong Lukang Pharmaceutical Co LtdNo. 88, Deyuan Road, High-Tech ZoneJINING 272000ChinaCHN
- Phone+86 5 372983174
- Fax+86 5 372983097
- Websitehttps://www.lkpc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pulike Biological Engineering Inc | 1.33bn | 220.37m | 6.03bn | 1.72k | 27.29 | 2.20 | -- | 4.53 | 0.6387 | 0.6387 | 3.86 | 7.91 | 0.4027 | 2.88 | 3.16 | 774,651.60 | 6.67 | 8.40 | 7.93 | 9.75 | 60.80 | 63.63 | 16.56 | 19.68 | 2.34 | 33.56 | 0.0173 | 49.78 | 11.78 | 18.30 | -28.68 | 8.80 | 43.18 | 11.84 |
| Sichuan Huiyu Pharmaceutical Co Ltd | 931.96m | 147.83m | 6.08bn | 1.36k | 41.12 | 1.59 | -- | 6.52 | 0.349 | 0.349 | 2.20 | 9.01 | 0.2032 | 0.9121 | 14.88 | 683,254.60 | 3.18 | 10.41 | 3.82 | 12.76 | 84.46 | 89.89 | 15.65 | 21.42 | 2.92 | -- | 0.1299 | 20.54 | -37.92 | 76.37 | -43.86 | -- | 66.72 | -- |
| Jiangsu Aidea Pharmaceutical Co Ltd | 391.64m | -90.16m | 6.22bn | 476.00 | -- | 5.58 | -- | 15.88 | -0.2106 | -0.2106 | 0.9303 | 2.65 | 0.227 | 1.23 | 1.98 | 822,765.80 | -5.23 | -2.40 | -7.18 | -2.85 | 44.46 | 39.00 | -23.02 | -10.15 | 1.20 | -- | 0.2992 | -- | 68.44 | 8.24 | 38.75 | -- | -4.47 | -- |
| Beijing Sun-Novo Pharma Research Co Ltd | 951.95m | 209.57m | 6.31bn | 1.37k | 30.11 | 6.22 | -- | 6.63 | 1.87 | 1.87 | 8.50 | 9.06 | 0.5465 | 26.19 | 1.77 | 694,854.30 | 11.70 | 12.99 | 19.13 | 21.70 | 59.10 | 53.93 | 21.40 | 21.34 | 1.77 | 45.00 | 0.3721 | 10.74 | 37.76 | 47.22 | 18.08 | 54.90 | 34.77 | -- |
| Shandong Lukang Pharmaceutical Co Ltd | 6.28bn | 267.79m | 6.40bn | 6.48k | 24.45 | 1.74 | -- | 1.02 | 0.292 | 0.292 | 6.88 | 4.11 | 0.7187 | 3.54 | 6.45 | 967,865.70 | 3.21 | 2.21 | 5.51 | 4.05 | 23.55 | 23.41 | 4.47 | 3.46 | 0.7313 | 5.39 | 0.4689 | 31.79 | 9.34 | 13.04 | 78.37 | 8.81 | -16.95 | 23.94 |
| Guizhou Sanli Pharmaceutical Co Ltd | 1.46bn | 255.61m | 6.42bn | 1.56k | 25.07 | 4.69 | -- | 4.39 | 0.6247 | 0.6247 | 3.57 | 3.34 | 0.8126 | 2.95 | 4.72 | 938,139.90 | 14.13 | 13.13 | 19.59 | 16.50 | 72.49 | 68.60 | 17.39 | 15.49 | 2.01 | -- | 0.125 | 20.67 | 27.94 | 13.48 | 32.18 | 18.10 | 75.64 | -- |
Data as of Mar 13 2024. Currency figures normalised to Shandong Lukang Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
2.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2023 | 11.33m | 1.28% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 4.52m | 0.51% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.43m | 0.27% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2023 | 2.06m | 0.23% |
| China Asset Management Co., Ltd.as of 30 Jun 2023 | 1.18m | 0.13% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 1.03m | 0.12% |
| E Fund Management Co., Ltd.as of 30 Jun 2023 | 558.50k | 0.06% |
| GF Fund Management Co., Ltd.as of 30 Jun 2023 | 514.90k | 0.06% |
| Gfund Management Co., Ltd.as of 30 Jun 2023 | 484.20k | 0.05% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2023 | 201.60k | 0.02% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
